Literature DB >> 9557954

A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection.

A Horváth1, G K Tóth, P Gogolák, Z Nagy, I Kurucz, I Pecht, E Rajnavölgyi.   

Abstract

Multipeptide constructs, comprising adjacent sequences of the 317-341 intersubunit region of immature influenza A hemagglutinin (H1N1), were designed and the functional properties of these branched peptides were compared to that of the corresponding linear peptides. In vivo studies revealed that the immunogenicity of the peptides was dependent on the presence of the hydrophobic fusion peptide (comprised in FP3), encompassing the N-terminal 1-13 sequence of the HA2 subunit. Antibody and T cell recognition, however, was directed against the 317-329 HA1 sequence, comprised in the P4 peptide. Multiple copies of P4, covalently linked by branched lysine residues, significantly enhanced the efficiency of antibody binding and the capacity of peptides to elicit B- and T-cell responses. A fraction of peptide induced antibodies reacted with immature or with proteolitically cleaved hemagglutinin (HA) molecules pretreated at low pH. Immunization with a multipeptide construct, (P4)4-FP3, not only resulted in elevated antibody and T cell responses but conferred enhanced protection against lethal A/PR/8/34 (H1N1) infection as compared to its subunit peptides. The beneficial functional properties of this artificial peptide antigen may be acquired by multiple properties including: (i) stabilized peptide conformation which promotes strong, polyvalent binding to both antibodies and MHC class II molecules; (ii) appropriate P4 conformation for antibody recognition stabilized by the covalently coupled fusion peptide, resulting in the production of virus cross reactive antibodies which inhibit the fusion activity of the virus; (iii) activation of peptide specific B cells which potentiate antigen presentation and peptide specific T cell responses; and (iv) generation of helper T cells which secrete lymphokines active in the resolution of infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557954     DOI: 10.1016/s0165-2478(97)00137-5

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  10 in total

Review 1.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

2.  Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.

Authors:  Elisabetta Bianchi; Xiaoping Liang; Paolo Ingallinella; Marco Finotto; Michael A Chastain; Jiang Fan; Tong-Ming Fu; Hong Chang Song; Melanie S Horton; Daniel C Freed; Walter Manger; Emily Wen; Li Shi; Roxana Ionescu; Colleen Price; Marc Wenger; Emilio A Emini; Riccardo Cortese; Gennaro Ciliberto; John W Shiver; Antonello Pessi
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 3.  The prospects and challenges of universal vaccines for influenza.

Authors:  Kanta Subbarao; Yumiko Matsuoka
Journal:  Trends Microbiol       Date:  2013-05-17       Impact factor: 17.079

Review 4.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

5.  Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.

Authors:  Nayana Prabhu; Mookkan Prabakaran; Hui-Ting Ho; Sumathy Velumani; Jia Qiang; Michael Goutama; Jimmy Kwang
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

6.  A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Authors:  Chia-Ying Wu; Yi-Chun Yeh; Jia-Tsrong Chan; Yu-Chih Yang; Ji-Rong Yang; Ming-Tsan Liu; Ho-Sheng Wu; Pei-Wen Hsiao
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

Review 7.  Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.

Authors:  Zuzana Staneková; Eva Varečková
Journal:  Virol J       Date:  2010-11-30       Impact factor: 4.099

8.  Prospects for universal influenza virus vaccine.

Authors:  Walter Gerhard; Krystyna Mozdzanowska; Darya Zharikova
Journal:  Emerg Infect Dis       Date:  2006-04       Impact factor: 6.883

9.  Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.

Authors:  Miriam Klausberger; Rupert Tscheliessnig; Silke Neff; Raffael Nachbagauer; Teddy John Wohlbold; Monika Wilde; Dieter Palmberger; Florian Krammer; Alois Jungbauer; Reingard Grabherr
Journal:  PLoS One       Date:  2016-04-18       Impact factor: 3.240

10.  Masking terminal neo-epitopes of linear peptides through glycosylation favours immune responses towards core epitopes producing parental protein bound antibodies.

Authors:  Robert Pon; Anne Marcil; Wangxue Chen; Christine Gadoury; Dean Williams; Kenneth Chan; Hongyan Zhou; Amalia Ponce; Eric Paquet; Komal Gurnani; Anindita Chattopadhyay; Wei Zou
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.